The management of osteoporosis in breast cancer survivors

Taxel, Pamela; Choksi, Palak; Poznak, Catherine Van

doi:10.1016/j.maturitas.2012.08.009

Cited by 33 publications

(30 citation statements)

References 42 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The bisphosphonates have been shown to be effective in reducing vertebral as well as hip fractures in postmenopausal women [78]. Studies of bisphosphonates in women with breast cancer demonstrate a decrease in the rate of bone loss and increases in BMD [79]. Denosumab inhibits RANKL and thereby the activation of osteoclasts, reducing bone turnover.…”

Section: Prevention and Treatment Of Osteoporosismentioning

confidence: 99%

Skeletal Manifestations of Treatment of Breast Cancer

Choksi

Williams

Clark

et al. 2013

Curr Osteoporos Rep

Self Cite

View full text Add to dashboard Cite

Breast cancer and osteoporosis are common diagnoses in women. Breast cancer survival has improved due to earlier detection and improved treatments. As most breast cancers are estrogen receptor positive, treatment is often aimed at altering the hormonal environment. Both pre and postmenopausal women undergoing these therapies are at risk for bone loss. The patient's health care team ought to have an awareness of the potential for breast cancer treatments to accelerate bone loss. Women with early stage breast cancer are treated with curative intent and, therefore, maintaining bone health is important and is part of the survivorship care to ensure an optimal quality of life.

show abstract

Section: Prevention and Treatment Of Osteoporosismentioning

confidence: 99%

Skeletal Manifestations of Treatment of Breast Cancer

Choksi

Williams

Clark

et al. 2013

Curr Osteoporos Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Research on the late effects of breast cancer has focused on pre-specified hypotheses pertaining to particular organ systems—such as the cardiovascular system [3], reproductive system [4], and bone health [5]—or pertaining to particular functional consequences, such as loss of shoulder function [6,7] or quality of life [8]. Alternatively, research has been organized according to the adverse effects potentially related to radiation therapy [9], chemotherapy [10], or adjuvant endocrine therapies [11].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer

Lash

Thwin

Yood

et al. 2014

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Late effects of breast cancer affect the quality of survivorship. Using administrative data, we compared the occurrence of almost all ICD9 codes among older breast cancer survivors to that among a matched comparison cohort to generate new hypotheses. Methods Breast cancer patients sixty-five years or older diagnosed 1990–1994 in six integrated care settings and who survived at least five years were matched with a cohort of women without a history of breast cancer on care setting, age, and calendar time. We collected data on the occurrence of incident ICD9 codes beginning six years after the breast cancer diagnosis date and continuing to year fifteen, and comparable data for the matched woman. We calculated hazard ratios and 95% confidence intervals associating breast cancer survivorship with incidence of each ICD9 code. We used semi-Bayes methods to address multiple comparisons. Results Older breast cancer survivors had about the same occurrence of diseases and conditions six to fifteen years after breast cancer diagnosis as comparable women. The median of 564 adjusted hazard ratios equaled 1.06, with interquartile range 0.92 to 1.3. The distribution of hazard ratios pertaining to cancer-related ICD codes was shifted towards positive associations, and the distribution pertaining to cardiovascular-related ICD codes was shifted towards negative associations. Conclusions In this hypothesis scanning study, we observed little difference in the occurrence of non-breast cancer-related diseases and conditions among older, long-term breast cancer survivors and comparable women without a history of breast cancer.

show abstract

“…Many older breast cancer patients receive adjuvant hormonal therapy. While tamoxifen is associated with a decreased risk of osteoporosis if used in postmenopausal women, it may lead to an increase in the incidence of osteoporosis in premenopausal women 54 . Compared to tamoxifen, aromatase inhibitors (AIs) are associated with higher risk of low bone density and fractures 55 .…”

Section: Chronic Toxicity From Cancer Therapymentioning

confidence: 99%